Novel therapies and approaches to relapsed/refractory HL beyond chemotherapy

Alain Antoine Mina, Chetan Vakkalagadda, Barbara Pro*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Although Hodgkin lymphoma (HL) is highly curable with first-line therapy, relapses occur in approximately 10–20% of patients with early stage disease and 30–40% of patients with advanced stage disease. The standard approach for relapsed or refractory disease is salvage therapy, followed by consolidation with high dose therapy and autologous stem cell transplant (ASCT). Patients who achieve a complete response to salvage therapy prior to ASCT have better outcomes, thus recent studies have focused on incorporating newer agents in this setting. Major challenges in the management of relapsed patients remain how to choose and sequence the many salvage therapies that are currently available and how to best incorporate novel agents in the current treatment paradigms. In this article, we will summarize the most recent advances in the management of patients with recurrent HL and will mainly focus on the role of new agents approved and under investigation. Aside from brentuximab vedotin and checkpoint inhibitors, other novel agents and therapies are showing promising early results. However, at least with some of the newest targeted strategies, it is important to recognize that we are facing new challenges in terms of toxicities, which require very close monitoring and education of both the patient and treating physician.

Original languageEnglish (US)
Article number421
Issue number3
StatePublished - Mar 2019


  • Classical Hodgkin lymphoma
  • Refractory disease
  • Relapsed disease
  • Salvage therapy
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Novel therapies and approaches to relapsed/refractory HL beyond chemotherapy'. Together they form a unique fingerprint.

Cite this